AI Analysis of 400,000 Reddit Posts Reveals Overlooked Symptoms Linked to Popular GLP-1 Drugs
September 13, 2026 โ University of Pennsylvania School of Engineering and Applied Science
Artificial intelligence is giving researchers a new way to listen to what patients are saying about popular GLP-1 drugs. After analyzing more than 400,000 Reddit posts, a University of Pennsylvania team identified several symptoms reported by people using semaglutide (Ozempic, Wegovy, and Rybelsus) and tirzepatide (Mounjaro and Zepbound) that may not be fully represented in clinical trials or official regulatory information.
The study, published recently in Nature Health, examined more than five years of posts from nearly 70,000 Reddit users. Two categories stood out as particularly deserving of further investigation: reproductive symptoms, including changes in menstrual cycles, and problems involving body temperature, such as chills and hot flashes.
The findings do not establish that the medications caused these symptoms. Instead, researchers say the massive collection of spontaneous patient reports may reveal signals worth examining more closely.
"Some of the side effects we found, like nausea, are well known, and that shows that the method is picking up a real signal," says Sharath Chandra Guntuku, Research Associate Professor in Computer and Information Science (CIS) at Penn Engineering and the study's senior author. "The underreported symptoms are leads that came from patients themselves, unprompted, and clinicians could potentially pay attention to them."
What Patients Report Outside Clinical Trials
Clinical trials are designed to determine whether treatments work and to identify important safety problems, but they cannot necessarily capture every symptom that matters to patients once a medication reaches the market. By mining public discussions on Reddit, the Penn Engineering team has shown how AI can surface potential safety signals that may go undetected in controlled study environments.
As GLP-1 medications continue to see widespread global use in 2026 โ with millions of prescriptions filled annually for diabetes and weight management โ the need for real-world evidence has never been greater. The researchers caution that their findings are exploratory and not proof of causation, but they highlight how patient-generated data can complement traditional pharmacovigilance systems.
What's Next
Looking ahead, the researchers suggest that AI-driven analysis of patient forums could serve as an early-warning system for regulators and clinicians, flagging symptoms that warrant formal investigation. With the GLP-1 market projected to expand further, integrating such tools into post-market surveillance could help ensure that patient experiences inform the next generation of clinical guidance and drug labeling.